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Epithelial cell migration is crucial for the develop-
ment and regeneration of epithelial tissues. Aberrant
regulation of epithelial cell migration has a major
role in pathological processes such as the develop-
ment of cancer metastasis and tissue fibrosis. Here,
we report that in response to factors that promote
cell motility, the Rap guanine exchange factor
RAPGEF2 is rapidly phosphorylated by I-kappa-B-
kinase-b and casein kinase-1a and consequently
degraded by the proteasome via the SCFbTrCP ubiq-
uitin ligase. Failure to degrade RAPGEF2 in epithelial
cells results in sustained activity of Rap1 and inhibi-
tion of cell migration induced by HGF, a potent
metastatic factor. Furthermore, expression of a
degradation-resistant RAPGEF2 mutant greatly
suppresses dissemination and metastasis of human
breast cancer cells. These findings reveal a molecu-
lar mechanism regulating migration and invasion of
epithelial cells and establish a key direct link be-
tween IKKb and cell motility controlled by Rap-
integrin signaling.
INTRODUCTION
Epithelial cell migration and invasiveness are crucial for morpho-
genesis during embryonic development and for tissue regenera-
tion. In these processes, epithelial cells lose cell-cell adhesion,
develop a mesenchymal cell polarity and, eventually, acquire a
highly motile phenotype that enables the invasion of surrounding
tissues (Thiery, 2002; Yang and Weinberg, 2008). This biological
process, known as epithelial-mesenchymal transition (EMT), has
been implicated in diseases such as fibrosis and carcinoma
development. Understanding the molecular mechanisms con-574 Developmental Cell 27, 574–585, December 9, 2013 ª2013 Elsevtrolling epithelial cell migration is key to develop strategies that
may have clinical potential.
Rap, a small guanosine triphosphatase (GTPase) of the Ras
family, is a major regulator of cell polarity, adhesion, and migra-
tion (Boettner and Van Aelst, 2009; Bos, 2005). It was originally
identified as a protein able to revert the transformed phenotype
of K-Ras (Kitayama et al., 1989). Biochemical and genetic
studies in various model systems have revealed that Rap is a
potent activator of integrins (Duchniewicz et al., 2006; Katagiri
et al., 2000; Reedquist et al., 2000; Sebzda et al., 2002). Indeed,
a number of growth factors and cytokines stimulate integrin-
mediated cell adhesion through the activation of Rap. In
addition, Rap is required for the formation and maintenance of
E-cadherin-mediated cell-cell adhesion independently of its
effects on integrins (Hogan et al., 2004; Knox and Brown,
2002; Kooistra et al., 2007; Price et al., 2004).
As other small GTPases, Rap acts as a molecular switch by
cycling between inactive GDP-bound and active GTP-bound
forms. The transition between these two conformations is tightly
controlled by specific guanine nucleotide exchange factors
(GEFs), which promote the conversion from the inactive GDP-
bound conformation into the active GTP-bound conformation
and GTPase-activating proteins (GAPs), which stimulate the
intrinsic hydrolytic GTPase activity accelerating the conversion
into the inactive GDP-bound form. Rap activity is regulated by
a multitude of extracellular signals, which control distinct Rap
GEFs and GAPs (Pannekoek et al., 2009). Among them,
RAPGEF2 (also known as PDZGEF1, CNRASGEF, NRAPGEP,
RA-GEF-1) specifically activates Rap1 and its close relative
Rap2 in vitro and in vivo by stimulating GDP-GTP exchange
(de Rooij et al., 1999; Kuiperij et al., 2003; Liao et al., 1999; Oht-
suka et al., 1999; Rebhun et al., 2000). Genetic approaches have
shown that the Caenorhabditis elegans homolog of RAPGEF2,
pxf-1, is required for Rap-mediated maintenance of epithelial
integrity (Pellis-van Berkel et al., 2005). In Drosophila, loss of
function mutants of dPDZGEF/Dizzy display defective develop-
ment of various organs including eye, wing, and ovary (Lee
et al., 2002). In particular, dPDZGEF controls the formation ofier Inc.
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lium (Spahn et al., 2012). Moreover, deletion of dPDZGEF results
in loss of both germline and somatic stem cells due to an impair-
ment of adherens junctions at the hub-stem cell interface (Wang
et al., 2006). RAPGEF2/ mouse embryos die between E11.5
and E12.5 with severe organogenesis defects, indicating that
RAPGEF2 is essential for embryonic development inmice (Bilasy
et al., 2009; Satyanarayana et al., 2010; Wei et al., 2007). Alto-
gether, these genetic studies indicate that RAPGEF2 plays a
fundamental role in the development and maintenance of
epithelia, however, the molecular mechanisms that regulate
RAPGEF2 levels and functions remain largely unknown.
SCF ubiquitin ligases target key cellular regulatory proteins for
ubiquitin-mediated proteolysis (Cardozo and Pagano, 2004; Jin
et al., 2004). They are composed of the core subunits Skp1,
Cul1, Rbx1, and one of many F-box proteins that serve as
specific substrate-receptor subunits. SCFbTrCP has been impli-
cated in the degradation of proteins controlling cell cycle pro-
gression, apoptosis, circadian rhythms, and differentiation
(Frescas and Pagano, 2008). All substrates of SCFbTrCP contain
a conserved destruction motif with the consensus DSGXX(X)S,
which, once phosphorylated, mediates the binding to the
WD40 b-propeller structure of bTrCP. Mammals express two
paralogous bTrCP proteins (bTrCP1, also known as FBXW1,
and bTrCP2, also called FBXW11), yet their biochemical proper-
ties are indistinguishable. Wewill therefore use the term bTrCP to
refer to both, unless specified otherwise.
Here, we show that, in response to metastatic factors,
RAPGEF2 is rapidly phosphorylated by CK1a on a conserved
degron and ubiquitylated by SCFbTrCP. CK1a-mediated phos-
phorylation of RAPGEF2 is stimulated by IKKb, which phosphor-
ylates RAPGEF2 on Ser1254. RAPGEF2 ubiquitylation triggers
its proteasome-dependent degradation, enabling inactivation
of Rap1 and induction of cell motility. Remarkably, inhibition of
RAPGEF2 proteolysis blocks migration of epithelial cells and
suppresses metastasis of breast cancer cells. Thus, CK1a-
and IKKb-dependent degradation of RAPGEF2 represents a crit-
ical event required for epithelial cell migration and invasion.
RESULTS
Rapid bTrCP-Dependent Degradation of RAPGEF2 in
Response to Stimuli that Induce Cell Migration
To identify substrates of the SCFbTrCP ubiquitin ligase, we used
an immunoaffinity assay followed by mass spectrometry anal-
ysis (Kruiswijk et al., 2012; Low et al., 2013). HEK293T cells
were transfected with FLAG-HA epitope-tagged bTrCP2 and
treated with the proteasome inhibitor MG132. Proteins that
coimmunoprecipitated with FLAG-HA-bTrCP2 were analyzed
by liquid chromatography-tandem mass spectrometry. We
recovered 14 peptides corresponding to the Rap guanine nucle-
otide exchange factor RAPGEF2 (Figure S1A available online).
We then followed the reciprocal approach and immunopurified
FLAG-HA epitope-tagged RAPGEF2 from HEK293T cells. We
identified 7, 14, 3, 2, and 1 peptides derived from the SCF
subunits bTrCP1, bTrCP2, Skp1, Cul1, and Rbx1, respectively
(Figure S1B). In addition, peptides corresponding to the small
GTPases Rap1 (isoforms A and B) and Rap2 (isoforms B and
C) were detected in the RAPGEF2 immunopurification (Fig-Developmure S1C). Of note, we never observed other members of the
Ras family of small G-proteins when we used RAPGEF2 as bait.
To verify the specificity of the bTrCP-RAPGEF2 binding, we
immunoprecipitated a number of FLAG epitope-tagged F-box
proteins as well as the related proteins Cdh1 and Cdc20 from
HEK293T cells and examined their ability to pull-down endoge-
nous RAPGEF2. bTrCP1 and its paralog bTrCP2 coimmunopre-
cipitated with endogenous RAPGEF2 (Figure 1A), whereas other
members of the FBXW family of F-box proteins, FBXW2, FBXW4,
FBXW5, FBXW7, FBXW8, or the APC/C activators Cdh1 and
Cdc20 (also containing WD40 repeats) did not. A complex with
the endogenous bTrCP and RAPGEF2 proteins was also
observed (Figure 1B).
It has been shown that the WD40 b-propeller structure of
bTrCP is required for the interaction with its substrate proteins
and thatmutation of a specific arginine residue (Arg447 of human
bTrCP2, isoformC) in theWD40 repeats abolishes both the bind-
ing and ubiquitin conjugation of the substrate (Kruiswijk et al.,
2012; Wu et al., 2003). To determine if the WD40 b-propeller
structure of bTrCP is responsible for the binding to RAPGEF2,
we expressed in HEK293T cells wild-type bTrCP2 and the
bTrCP2(R447A) mutant, which were then immunoprecipitated.
Whereas wild-type bTrCP2 immunoprecipitated endogenous
RAPGEF2 and the established substrate b-catenin, the
bTrCP2(R447A) mutant did not (Figure 1C).
To test whether RAPGEF2 is a substrate of the SCFbTrCP ubiq-
uitin ligase, we reconstituted the ubiquitylation of RAPGEF2
in vitro. bTrCP1, but not an inactive bTrCP1(DF box) mutant,
was able to efficiently ubiquitylate RAPGEF2 (Figure 1D).
Before examining a putative function of the SCFbTrCP ubiquitin
ligase in targeting RAPGEF2 for degradation, we sought to find
under which condition RAPGEF2 is degraded in the cell. As
Rap1 is a key mediator of cell adhesion, we hypothesized that
RAPGEF2 may be downregulated in response to stimuli that
disrupt cell adhesion and induce cell migration. To test this
hypothesis, we analyzed RAPGEF2 protein levels in epithelial
Madin-Darby canine kidney (MDCK) cells treated with hepato-
cyte growth factor/scatter factor (HGF/SF). This is a well-estab-
lished in vitro model system that has been extensively used to
study the mechanisms by which epithelial cells become migra-
tory, mesenchymal-like cells. HGF is known to induce centrifugal
spreading of MDCK cell colonies, loss of cell-cell adhesion, and
increase in cell motility without stimulating cell growth (Gherardi
et al., 1989; Stoker et al., 1987; Stoker and Perryman, 1985;
Tanimura et al., 1998). Figure 1E shows that RAPGEF2 levels
rapidly decreased in response to HGF. The proteasome inhibitor
MG132 prevented the decrease of RAPGEF2, indicating that
RAPGEF2 degradation is mediated by the proteasome.
RAPGEF2 destruction was also triggered following treatment
with phorbol-12-myristate-13-acetate (PMA) (Figure 1F), which
is known to induce a marked scattering of MDCK cells without
affecting significantly cell proliferation (Rosen et al., 1991; Tani-
mura et al., 1998), but not in response to a number of other
growth factors, such as epidermal growth factor (EGF) or insu-
lin-like growth factor (IGF), which do not induce scattering of
MDCK cells (Tanimura et al., 1998) (Figures S1D and S1E). Pro-
teasome-dependent degradation of RAPGEF2 was observed
upon HGF treatment of human epithelial kidney HEK293 cells
(Figure S1F), which form epithelial layers similar to MDCK cellsental Cell 27, 574–585, December 9, 2013 ª2013 Elsevier Inc. 575
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Figure 1. RAPGEF2 Is Targeted for Degradation by SCFbTrCP in Response to Stimuli that Induce Cell Migration
(A) The indicated FLAG-tagged F-box proteins (FBPs), the APC/C activators Cdh1 and Cdc20 or an empty vector (EV) were expressed in HEK293T cells. Forty-
eight hours after transfection, cells were treated for 5 hr with the proteasome inhibitor MG132, then harvested and lysed. Whole cell extracts were immuno-
precipitated (IP) with anti-FLAG resin and immunoblotted with the indicated antibodies. AB1 and AB2 are two different anti-RAPGEF2 antibodies.
(B) HEK293T cells were treated for 5 hr with the proteasome inhibitor MG132, then harvested and lysed. Whole cell extracts were immunoprecipitated (IP) with
anti-RAPGEF2 antibody and immunoblotted with the indicated antibodies.
(C) Arg447 in theWD40 repeat of bTrCP2 is required for the interaction with RAPGEF2. HEK293T cells were transfected as indicated and analyzed as in (A). WCE,
whole cell extract; WT, wild-type.
(D) RAPGEF2, Skp1, Cul1, and Rbx1 were expressed in HEK293T cells in the absence or presence of FLAG-tagged bTrCP1 or a FLAG-tagged bTrCP1(DF-box)
mutant. After immunopurification with anti-FLAG resin, in vitro ubiquitylation of RAPGEF2 was performed as described in the Supplemental Experimental
Procedures. Samples were analyzed by immunoblotting with an anti-RAPGEF2 antibody. The bracket indicates a ladder of bands corresponding to poly-
ubiquitylated RAPGEF2.
(E and F) MDCK cells were treated with HGF (E) or PMA (F) with or without the proteasome inhibitor MG132. Cells were collected at the indicated times and lysed.
Whole cell extracts were subjected to immunoblotting with the indicated antibodies. Actin is shown as a loading control.
(G) HEK293 cells were transfected with the indicated siRNA oligonucleotides and treated with PMA. Cells were then collected and analyzed as in (E).
(H and I) HEK293 cells were transfected with an empty vector or FLAG-tagged bTrCP1. Forty-eight hours after transfection, cells were treated, when indicated,
with MG132 and with either HGF (H) or PMA (I) for 4 hr, then harvested and lysed. Whole cell extracts were immunoprecipitated (IP) with anti-FLAG resin, and
immunoblotted with anti-RAPGEF2 and anti-FLAG antibodies.
See also Figure S1.
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RAPGEF2 Degradation Controls Cell Migrationand have an intact HGF signaling (Sakkab et al., 2000). The
degradation of RAPGEF2 in response to the motogenic stimulus
is a rapid event that starts much earlier than the downregulation
of E-cadherin, suggesting that the degradation of RAPGEF2 is
not an indirect consequence of cell junction disassembly (data
not shown).
To test whether the degradation of RAPGEF2 observed in
response to factors that induce cell migration is mediated by
bTrCP, we reduced the levels of both bTrCP1 and bTrCP2 in
HEK293 cells using a previously validated siRNA (Guardavac-576 Developmental Cell 27, 574–585, December 9, 2013 ª2013 Elsevcaro et al., 2008; Kruiswijk et al., 2012). We found that bTrCP
knockdown blocked the PMA-induced degradation of RAPGEF2
(Figure 1G). Accordingly, the binding of bTrCP to endogenous
RAPGEF2 was stimulated by both HGF and PMA (Figures 1H
and 1I).
HGF-Induced Phosphorylation of RAPGEF2 by CK1a
Triggers RAPGEF2 Degradation
The WD40 b-propeller structure of bTrCP interacts with its
substrate proteins via a diphosphorylated degradation motifier Inc.
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and Pagano, 2004; Frescas and Pagano, 2008; Wu et al.,
2003). We identified one canonical DpSGXX(X)pS motif in
human RAPGEF2 that might potentially be the phosphodegron
(Figure S2A). We mutated the serine residues in this motif to
alanine and determined the ability of the RAPGEF2 mutant to
interact with bTrCP. Whereas wild-type RAPGEF2 immunopre-
cipitated bTrCP1, the RAPGEF2(S1244A/S1248A) mutant did
not (Figure 2A). The motif surrounding S1244 and S1248
is highly conserved in vertebrate orthologs of RAPGEF2
(Figure 2B).
As a further method to examine whether phosphorylation is
required for the interaction of RAPGEF2 with bTrCP, we used
immobilized synthetic peptides comprising the bTrCP-binding
domain of RAPGEF2 (aa 1240–1252 in human RAPGEF2). As
shown in Figure 2C, a RAPGEF2-derived peptide containing
phosphoserine residues at positions Ser1244 and Ser1248
associated with in vitro translated bTrCP1, but not with a
different F-box protein, whereas the unphosphorylated peptide
did not associate at all, suggesting that phosphorylation of
Ser1244 and Ser1248 directly mediates the association with
bTrCP.
To investigate whether Ser1244 and Ser1248 are phos-
phorylated in vivo in response to factors that induce cell motility,
we generated a phosphospecific antibody against the
1240DAADpSGRGpSWTSC1252 peptide with phosphoserine
residues at positions 1244 and 1248. This antibody detected
wild-type RAPGEF2, but not the RAPGEF2(S1244A/S1248A)
mutant (Figure S2B). Moreover, l-phosphatase treatment of
immunoprecipitated wild-type RAPGEF2 inhibited RAPGEF2
detection by the phosphospecific antibody (Figure S2C). We
then used this antibody to test whether RAPGEF2 is phosphory-
lated in vivo. Figure 2D shows that RAPGEF2 was phosphory-
lated on Ser1244 and Ser1248 in HEK293 cells that were treated
with HGF.
In the RAPGEF2 immunopurification described above, we also
recovered three peptides corresponding to casein kinase 1
(CK1, isoform a; Figure S2D).We first confirmed that CK1a coim-
munoprecipitated with RAPGEF2 in vivo (Figure S2E). To test
whether CK1a is involved in the phosphorylation of RAPGEF2,
we used pharmacological inhibitors and found that the CK1
inhibitors D4476 and IC261 prevented both the HGF-induced
binding of bTrCP1 to RAPGEF2 and the phosphorylation of
RAPGEF2 on Ser1244/Ser1248 (Figure 2E). Accordingly,
D4476 blocked the HGF-induced degradation of RAPGEF2 (Fig-
ure 2F). To rule out nonspecific effects of these inhibitors, we
silenced CK1a by RNAi (Gao et al., 2011; Tapia et al., 2006).
The knockdown of CK1a inhibited the proteasome-dependent
degradation of RAPGEF2 in response to HGF (Figure 2G) as
well as RAPGEF2 interaction with bTrCP (Figure 2H).
In order to determine if CK1a directly phosphorylates the
RAPGEF2 degron, we carried out an in vitro kinase assay, using
purified recombinant CK1a. CK1a, but not CK2, GSK3b, or
CDK1 (kinases involved in the phosphorylation of other sub-
strates of bTrCP), phosphorylated the degron of RAPGEF2
in vitro, as shown by the recognition by our phosphospecific anti-
body (Figure 2I). Altogether these results indicate that
CK1a-mediated phosphorylation of RAPGEF2 on Ser1244/
Ser1248 is required for RAPGEF2 degradation induced by HGF.DevelopmIKKb-Mediated Phosphorylation of RAPGEF2 Is
Required for RAPGEF2 Degradation
Substrates of bTrCP are phosphorylated on their degrons
following an initial phosphorylation event that either generates
a binding site for the kinase phosphorylating the degron or
exposes an otherwise masked degron. We noticed a consensus
sequence for phosphorylation by I-kappa-B kinase (IKK) in close
proximity to the RAPGEF2 phosphodegron (Figure S3A). Phorbol
esters (PMA) and HGF have been shown to stimulate the activity
of IKKb in epithelial cells (Fan et al., 2005, 2007, 2009; Hah and
Lee, 2003; Huang et al., 2003; Mu¨ller et al., 2002). First, we
confirmed that treatment of epithelial cells with HGF or PMA
results in the activation of IKKb (Figure S3B). We then tested
whether IKKb is able to phosphorylate RAPGEF2 by performing
an in vitro kinase assay using recombinant kinases and immuno-
purified RAPGEF2, which had been previously dephosphory-
lated. IKKb, and to a lesser extent IKKa, were able to phosphor-
ylate RAPGEF2 (as shown by incorporation of radiolabeled
phosphate), however, no phosphorylation was detected by our
phosphospecific antibody on the RAPGEF2 degron (Figures 3A
and S3C), indicating that IKKa/b phosphorylates residues of
RAPGEF2 different from Ser1244 and Ser1248.
Next, we tested whether RAPGEF2 phosphorylation by IKKb
affects the CK1a-dependent phosphorylation of the RAPGEF2
degron in vitro. When purified recombinant IKKb was used to
phosphorylate RAPGEF2 (and washed away before CK1a addi-
tion), stimulation of the CK1a-mediated phosphorylation of the
RAPGEF2 degron was observed (Figures 3B and S3C). IKKa
did not have any effect on the CK1a-mediated phosphorylation
of the RAPGEF2 degron (Figure S3C). Accordingly, in cultured
cells, CK1a-mediated phosphorylation of the RAPGEF2 degron
(Figures 3C and 3D), RAPGEF2 binding to bTrCP (Figure 3D),
and RAPGEF2 ubiquitylation (Figure 3E) were stimulated by the
overexpression of wild-type IKKb and, more extensively, the
constitutively active IKKb(S177E/S181E) mutant.
To assess whether IKKb is involved in the degradation of
RAPGEF2, we overexpressed IKKb and analyzed the abundance
of RAPGEF2 in the absence or presence of the proteasome
inhibitor MG132. Overexpression of the constitutively active
IKKb(S177E/S181E) mutant, but not the constitutively inactive
IKKb(S177A/S181A) mutant, resulted in RAPGEF2 downregula-
tion, which was prevented by proteasomal inhibition (Figure 3F).
Conversely, knockdown of IKKb prevented both the HGF- and
the PMA-induced degradation of RAPGEF2 (Figures 3G, 3H,
and S3D). Accordingly, pharmacological inhibition of IKK
blocked both the CK1a-dependent phosphorylation of the
RAPGEF2 degron and RAPGEF2 binding to bTrCP (Figure 3I).
Further, we found that IKKb was coimmunoprecipitated with
RAPGEF2 in vivo (Figure S3E). Taken together, these results indi-
cate that IKKb-dependent phosphorylation of RAPGEF2 is
required for RAPGEF2 degradation induced by HGF and medi-
ated by bTrCP.
We then employed mass spectrometry to pinpoint the specific
RAPGEF2 sites targeted by IKKb. Immunopurified, dephos-
phorylated RAPGEF2 was subjected to an in vitro kinase assay
in the presence or absence of purified kinases, prior to mass
spectrometry analysis. We identified phosphopeptides contain-
ing phospho-Ser1254 in IKKb-treated RAPGEF2 samples (Fig-
ures S3F and S3G). These phosphopeptides were not found inental Cell 27, 574–585, December 9, 2013 ª2013 Elsevier Inc. 577
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Figure 2. CK1a-Dependent Phosphorylation of RAPGEF2 Is Required for Its Degradation
(A) HEK293T cells were transfectedwith an empty vector (EV), HA-taggedwild-type RAPGEF2, or HA-taggedRAPGEF2(S1244A/S1248A). Forty-eight hours after
transfection, cells were harvested and lysed. Whole cell extracts were subjected to immunoprecipitation (IP) with anti-HA resin, followed by immunoblotting with
the indicated antibodies.
(B) Alignment of the amino acid regions corresponding to the bTrCP-binding motif in RAPGEF2 orthologs and previously reported bTrCP substrates (top).
Schematic representation of Ser to Ala substitutions in the bTrCP-binding motif of RAPGEF2. The amino acidic sequence of the double mutant is shown (bottom).
(C) Ser1244 and Ser1248 in RAPGEF2 require phosphorylation to bind bTrCP1. 35S-bTrCP1 and 35S-FBXW5 were transcribed/translated in vitro and incubated
with beads coupled to peptides spanning the RAPGEF2 degron (unphosphorylated or phosphorylated). Beads were washed with Triton X-100 buffer and bound
proteins were eluted and subjected to electrophoresis and autoradiography. The first two lanes correspond to 10% of the in vitro translated protein inputs.
Peptide sequence spanning the RAPGEF2 degron is shown in the bottom panel.
(D) HEK293 cells expressing HA-tagged wild-type RAPGEF2 were treated with the proteasome inhibitor MG132 in the presence of absence of HGF. Cells were
collected and lysed.Whole cell extracts were subjected to direct immunoblottingwith the indicated antibodies or immunoprecipitation with anti-HA resin followed
by immunoblotting with the indicated antibodies. Cul1 is shown as a loading control.
(E) HEK293 cells were transfected with HA-taggedwild-type RAPGEF2 or HA-tagged RAPGEF2(S1244A/S1248A). Forty-eight hours after transfection, cells were
treated with HGF andMG132 for 4 hr in the presence of absence of the indicated kinase inhibitors. Cells were then harvested and lysed. Whole cell extracts were
immunoprecipitated (IP) with anti-HA resin and analyzed by immunoblotting.
(F) MDCK cells were treated with HGF and the indicated compounds. Cells were lysed and collected. Whole cell extracts were then immunoblotted with the
indicated antibodies. Actin is shown as a loading control.
(G) HEK293 cells were transduced with the indicated lentiviral shRNA vectors. Cells were then treated with HGF for the indicated times. Cells were collected and
lysed. Whole cell extracts were treated as in (F).
(H) HEK293 cells, treated as in (G), were transfected with FLAG-tagged bTrCP1. Cells were treated with HGF and MG132 for 4 hr. Cells were then harvested and
lysed. Whole cell extracts were immunoprecipitated (IP) with anti-FLAG resin, and analyzed by immunoblotting.
(I) The RAPGEF2 degron is phosphorylated by CK1a in vitro. Immunopurified wild-type RAPGEF2 or RAPGEF2(S1244A/S1248A) were first dephosphorylated by
treatment with lambda phosphatase and then incubated with the indicated purified kinases in the presence of ATP. Reactions were stopped by adding Laemmli
buffer and analyzed by immunoblotting.
See also Figure S2.
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no kinase was added to the assay. Mutation of Ser1254 to Ala in
RAPGEF2 inhibited (1) CK1a-dependent phosphorylation of the578 Developmental Cell 27, 574–585, December 9, 2013 ª2013 ElsevRAPGEF2 degron (Figure 3J, middle panel), (2) RAPGEF2 inter-
action with bTrCP (Figure 3J, top panel), and (3) RAPGEF2
turnover (Figure S3H). Altogether, results indicate thatier Inc.
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Figure 3. IKKb Stimulates the CK1a-Mediated Degradation of RAPGEF2
(A) Immunopurifiedwild-type RAPGEF2 andRAPGEF2(S1244A/S1248A) were first dephosphorylated by treatment with lambda phosphatase and then incubated
with the indicated purified kinases in the presence of g32P ATP. Reactions were stopped by adding Laemmli buffer, run on SDS-PAGE and analyzed by auto-
radiography (top panels) and immunoblotting (bottom panels).
(B) Immunopurified wild-type RAPGEF2 was first dephosphorylated by treatment with lambda phosphatase and then incubated with the indicated kinases.
Kinases were then washed away prior to addition of CK1a. Reactions were stopped at the indicated times and analyzed by immunoblotting.
(C and D) HEK293 cells were transfected with the indicated constructs. Cells were treated with HGF and MG132 for 4 hr. Cells were then harvested and lysed.
Whole cell extracts were immunoprecipitated (IP) with anti-HA resin, and immunoblotted with antibodies specific for the indicated proteins. Immunocomplexes
were treated with lambda phosphatase when indicated. CA, constitutively active.
(E) HEK293 cells, transfected with the indicated constructs, were treated as in (C), then harvested and lysed in 0.1% Triton X-100 lysis buffer. Whole cell extracts
were denatured by adding 1% SDS and boiling for 10 min. SDS was quenched and diluted. Whole cell extracts were then immunoprecipitated (IP) with anti-HA
resin, and immunoblotted with antibodies specific for the indicated proteins. The bracket indicates a ladder of bands corresponding to poly-ubiquitylated
RAPGEF2.
(F) HEK293were transfected with HA-tagged RAPGEF2 and the constitutively active IKKb(S177E/S181E) or inactive IKKb(S177A/S181A) mutant and treated with
MG132 in presence of HGF. After 48 hr, cells were collected, lysed and subjected to immunoblotting. CA, constitutively active; CI, constitutively inactive.
(G andH) Cells were transfectedwith the indicated siRNA oligonucleotides and treatedwith HGF only (G) or HGF and cycloheximide (H) to block protein synthesis.
Cells were then collected at the indicated times. Whole cell extracts were analyzed by immunoblotting. Cul1 is shown as a loading control.
(I) HEK293 cells were transfected with HA-tagged wild-type RAPGEF2. Forty-eight hours after transfection, cells were treated with HGF andMG132 for 4 hr in the
presence or absence of the IKK inhibitor SC-514. Cells were then harvested and lysed. Whole cell extracts were immunoprecipitated (IP) with anti-HA resin, and
immunoblotted with the indicated antibodies.
(J) HEK293 cells were transfected with an empty vector (EV), HA-tagged wild-type RAPGEF2, HA-tagged RAPGEF2(S1244A/S1248A), or HA-tagged
RAPGEF2(S1254A). Forty-eight hours after transfection, cells were treated with the proteasome inhibitor MG132 in the presence of HGF, then harvested and
lysed. Whole cell extracts were analyzed as in (I).
See also Figure S3.
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RAPGEF2 Degradation Controls Cell MigrationIKKb-mediated phosphorylation of RAPGEF2 on Ser1254
promotes the phosphorylation of the RAPGEF2 degron by
CK1a, RAPGEF2 binding to bTrCP, and RAPGEF2 degradation.
RAPGEF2 Degradation Controls the HGF-Induced
Migration of Epithelial Cells
To examine the biological function of RAPGEF2 degradation, we
transduced MDCK cells with lentiviruses expressing physiolog-
ical levels of wild-type RAPGEF2 or RAPGEF2(S1244A/
S1248A) (Figure S4A). We first confirmed that both the steady
state levels and the half-life of RAPGEF2(S1244A/S1248A)Developmwere increased when compared with wild-type RAPGEF2 in
MDCK cells treated with HGF (Figures 4A and 4B) or PMA (Fig-
ures S4B and S4C). As expected, growth factors that do not
induce scattering of MDCK cells, such as EGF and PDGF, did
not lead to degradation of either wild-type RAPGEF2 or
RAPGEF2(S1244A/S1248A) (Figures S4D and S4E). Notably,
the RAPGEF2(S1244A/S1248A) mutant that escaped degrada-
tion upon HGF stimulation localized to the plasma membrane
(Figure S4F).
Next, we examined whether RAPGEF2 degradation affected
the activity of Rap1 in response to HGF. Whereas in cellsental Cell 27, 574–585, December 9, 2013 ª2013 Elsevier Inc. 579
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Figure 4. RAPGEF2 Degradation Is Required for Rap1 Inactivation and Stimulation of Cell Migration in Response to HGF
(A and B) MDCK cells, transducedwith lentiviruses expressing HA-tagged wild-type RAPGEF2 or HA-tagged RAPGEF2(S1244A/S1248A), were treated with HGF
only (A) or HGF and the inhibitor of protein synthesis cycloheximide (B) for the indicated times. Cells were then collected and analyzed by immunoblotting. Actin
and Cul1 are shown as a loading control.
(C) MDCK cells, transduced as in (A), were treated with HGF for the indicated times. Cells were collected and lysed. Whole cell extracts were analyzed by
immunoblotting with the indicated antibodies and in a pull-down assay using a GST fusion of the activated Rap1-binding domain of RalGDS. The levels of
precipitated Rap1 were determined by immunoblotting using an anti-Rap1 antibody. The asterisk indicates a nonspecific band. Actin is shown as a loading
control. To facilitate comparison, a dotted line separates samples from cells expressing wild-type RAPGEF2 and samples from cells expressing
RAPGEF2(S1244A/S1248A). The graph shows the abundance of Rap1-GTP normalized to total Rap1 and relative to Rap1-GTP in cells expressing wild-type
RAPGEF2 at time 0. Values are averaged with the ones from three additional independent experiments (n = 4 ± SD).
(D) MDCK cells, transduced with lentiviruses expressing wild-type RAPGEF2 or RAPGEF2(S1244A/S1248A), were treated with HGF and imaged by time-lapse
phase-contrast microscopy for 16 hr. Representative phase-contrast images from the time-lapse series are shown. Scale bars represent 100 mm.
(E) Quantification of scattering from time-lapse experiments. The graph shows the number of islands scattered (islands in which cells have disrupted cell-cell
contacts) after HGF treatment. p < 0.001 (Pearson’s c2 test). Only islands including 5–15 cells were scored.
(F) An automated cell tracking software was employed to measure the average migration velocity of MDCK cells expressing wild-type RAPGEF2 or the
RAPGEF2(S1244A/S1248A) mutant in the presence of HGF. For each cell line/condition, three independent time-lapse image series (at least 300 individual cells)
were analyzed.
(G) Representative individual migratory tracks of MDCK cells expressing wild-type RAPGEF2 or RAPGEF2(S1244A/S1248A) in the presence of HGF.
(H) Track distance of individual cells shown in (G). Horizontal lines represent the mean. p < 0.001 (Student’s t test).
(I) MDCK cells expressing wild-type RAPGEF2 or the RAPGEF2(S1244A/S1248A) mutant were grown to confluence. Cell monolayers were wounded and then
treated with HGF. Cells were photographed immediately after wounding (0 hr) and after 4 (4 hr) and 8 hr (8 hr).
(J) The graph represents the relative wound closure at 0, 4, and 8 hr (n = 5 ± SD).
*p = 0.005 (Student’s t test). See also Figure S4.
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RAPGEF2 Degradation Controls Cell Migrationexpressing wild-type RAPGEF2, Rap1 was first rapidly activated
and then inactivated following HGF treatment (as shown by the
amount of the GTP-bound Rap1), cells expressing the stable
RAPGEF2 mutant displayed sustained Rap1 activity (Figure 4C).
On the contrary, Rap2 activity was neither regulated by HGF
treatment nor affected by RAPGEF2 degradation in HGF-treated
cells (data not shown).580 Developmental Cell 27, 574–585, December 9, 2013 ª2013 ElsevTo assess the effect of defective degradation of RAPGEF2 on
HGF-induced cell scattering, we employed a live-cell micro-
scopy assay (de Rooij et al., 2005; Loerke et al., 2012). MDCK
cells expressing physiological levels of wild-type RAPGEF2 or
RAPGEF2(S1244A/S1248A) were treated with HGF and followed
by time-lapse imaging (Figure 4D). We quantified cell scattering
by scoring the percentage of cell islands (groups of 5–16 cells) inier Inc.
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RAPGEF2 Degradation Controls Cell Migrationwhich three or more cells had disrupted contacts with neigh-
boring cells (Figure 4E). MDCK cells expressing the stable
RAPGEF2(S1244A/S1248A) mutant displayed decreased scat-
tering when compared with cells expressing wild-type
RAPGEF2. Next, we employed an automated cell tracking soft-
ware that tracks individual cell velocity and trajectories from
consecutive time-lapse images (de Rooij et al., 2005; Loerke
et al., 2012). As shown in Figure 4F, cells expressing the
RAPGEF2 stable mutant displayed defective induction of
average cell speed following HGF treatment. Accordingly,
individual migratory tracks of MDCK cells expressing
RAPGEF2(S1244AS1248A) treated with HGF were shorter
when compared with the ones of MDCK cells expressing wild-
type RAPGEF2 (Figures 4G and 4H).
Scattering of epithelial cells in response to HGF is character-
ized by two major steps, i.e., loss of cell adhesion, followed by
an increase in cell motility (Loerke et al., 2012). To assess in
which of these two processes the degradation of RAPGEF2 is
involved, we analyzed the motility of noncontacted cells (not
starting from cell islands) expressing wild-type RAPGEF2 or
the nondegradable RAPGEF2(S1244A/S1248A) mutant in
response to HGF. As shown in Figures S4G–S4I, HGF-induced
motility of noncontacted cells expressing RAPGEF2(S1244A/
S1248A) is reduced when compared with the one of noncon-
tacted cells expressing wild-type RAPGEF2 indicating that the
degradation of RAPGEF2 is required for the HGF-induced in-
crease in cell migration even in the absence of adherens
junctions.
To confirm that the nondegradable RAPGEF2 mutant inhibits
cell motility independently of cell-cell adhesion, we analyzed
the HGF-induced scattering in cells in which cell-cell junctions
were previously inhibited by low calcium conditions (Figures
S4J–S4M). Cells expressing the stable RAPGEF2 mutant
displayed a remarkable decrease in motility when compared
with cells expressing wild-type RAPGEF2 even in low calcium
conditions.
Taken together, these results indicate that RAPGEF2 degra-
dation is required for HGF-induced cell migration. As expected,
HGF-induced motility of MDCK cells was inhibited if RAPGEF2
degradation was bypassed by ectopic expression of the consti-
tutively active Rap1V12 mutant (Figures S4N–S4O).
As an additional method to analyze the role of RAPGEF2
degradation in cell migration, we employed the wound-healing
assay, which monitors the HGF-stimulated migration of cells
into a scratch made in a confluent monolayer of MDCK cells.
Following treatment with HGF, MDCK cells expressing the
nondegradable RAPGEF2(S1244A/S1248A) mutant were unable
to close the wound gap (Figures 4I and 4J).
Many studies have demonstrated that Rap1 controls inside-
out signaling regulating integrin activity (Arai et al., 2001; Bos
et al., 2001; Caron et al., 2000; Katagiri et al., 2000, 2003; Kinbara
et al., 2003; Reedquist et al., 2000; Sebzda et al., 2002). To test
whether the defective migration of MDCK cells expressing the
degradation-resistant RAPGEF2 mutant is linked to misregula-
tion of integrin activity, we analyzed the activity of b1-integrins
in HGF-treated MDCK cells using an antibody (9EG7) that
detects the active conformation of b1-integrins. As shown in Fig-
ures S4P and S4Q, untreatedMDCK cells expressing either wild-
type RAPGEF2 or RAPGEF2(S1244A/S1248A) displayed 9EG7Developmstaining mostly at the cell periphery. Whereas HGF treatment
of cells expressing wild-type RAPGEF2 resulted in a general
reduction of 9EG7 staining, it did not cause any detectable
change in the intensity of 9EG7 staining in MDCK cells ex-
pressing the degradation-resistant RAPGEF2 mutant. Of note,
the expression of b1-integrins did not change in response
to HGF either in control cells or in cells expressing the
RAPGEF2(S1244A/S1248A) mutant (data not shown). These
results indicate that in cells expressing the degradation-resistant
RAPGEF2mutant, defective stimulation of cell motility correlates
with misregulation of b1-integrins activity.
Failure to Degrade RAPGEF2 Inhibits Invasion and
Metastasis of Human Breast Cancer Cells
Next, we investigated the role of the CK1a-IKKb-bTrCP-
mediated degradation of RAPGEF2 in mediating tumor cell
invasion, dissemination, and metastasis. Highly metastatic
MDA-MB-231 breast cancer cells expressing physiological
levels of wild-type RAPGEF2 or RAPGEF2(S1244A/S1248A)
were assayed for their invasion potential in vitro using a standard
transwell assay. As shown in Figures 5A–5C, expression of
the degradation-resistant RAPGEF2(S1244A/S1248A) mutant
greatly inhibited the invasive migration of MDA-MB-231 cells
stimulated by HGF.
We then tested the metastatic potential of MDA-MB-231
breast cancer cells expressing the degradation-resistant
RAPGEF2 mutant using a zebrafish xenograft model for cancer
invasion-metastasis (Lee et al., 2009; Zhang et al.,
2012). We injected red-fluorescent-labeled MDA-MB-231 cells
expressing physiological levels of wild-type RAPGEF2 or
RAPGEF2(S1244A/S1248A) into the perivitelline space (ventrally
from the sub intestinal vein and anterior from the Duct of Cuvier)
of 48-hpf zebrafish embryos bearing green-fluorescent-labeled
endothelial cells [Tg(fli1a:eGFP)] (Figure 5D). Tumor cell dissem-
ination was examined in the trunk region 48 hr postinjection.
Strikingly, cells expressing wild-type RAPGEF2 (as well as
parental MDA-MB-231 cells) disseminated to the trunk region,
whereas cells expressing the nondegradable RAPGEF2 mutant
displayed a remarkably decreased ability to disseminate and
metastasize (Figures 5E–5G). Of note, neither the rate and
amount of neovascularization nor the tumor size of the xeno-
grafts showed apparent difference between the conditions.
DISCUSSION
In this study, we demonstrate that when cells are stimulated with
factors that induce cell motility, such as the metastatic factor
HGF, the Rap guanine nucleotide exchange factor RAPGEF2
is rapidly targeted for proteasome-dependent degradation by
the SCFbTrCP ubiquitin ligase in cooperation with IKKb and
CK1a. By phosphorylating RAPGEF2 on Ser1254, IKKb primes
RAPGEF2 for phosphorylation by CK1a on a conserved degron
(Ser1244/Ser1248) triggering RAPGEF2 ubiquitylation and
proteasomal degradation.
These findings reveal a molecular mechanism by which HGF-
MET signaling, which can be induced through paracrine and
autocrine production of HGF, stimulates epithelial cell motility.
By triggering the destruction of RAPGEF2, HGF induces the
inactivation of Rap1, a crucial regulator of the integrin function.ental Cell 27, 574–585, December 9, 2013 ª2013 Elsevier Inc. 581
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Figure 5. Expression of a Degradation-Resistant RAPGEF2 Mutant Blocks Invasion and Metastasis of Human Breast Cancer Cells
(A) MDA-MB-231 breast cancer cells, transduced with lentiviruses expressing HA-tagged wild-type RAPGEF2 or HA-tagged RAPGEF2(S1244A/S1248A), were
treated with HGF for the indicated times. Cells were then collected and analyzed by immunoblotting with the indicated antibodies. Cul1 is shown as a loading
control.
(B and C) MDA-MB-231 cells, transduced as in (A), were subjected to an in vitro invasion assay using HGF as chemoattractant as described in Supplemental
Experimental Procedures. Invading cells were stained with crystal violet. Representative photographs of three experiments are shown in (B). Quantification of
cells that invaded through the matrix is shown in (C). Data are mean ± SD of three experiments.
(D) Scheme of the zebrafish embryo and injections performed.
(E) MDA-MB-231 breast cancer cells expressing wild-type RAPGEF2 or RAPGEF2(S1244A/S1248A) were labeled with DiI and injected into the perivitelline space
of 48-hpf Tg(fli1a:eGFP) zebrafish embryos. Parental MDA-MB-321 cells were used as additional control. Dissemination of cancer cells were scored in the trunk
region 2 days postinjection using confocal microscopy. Representative micrographs of tumor and neovascularization (upper panel) and trunk region with
metastatic cells (lower panels) 48 hr postinjection are shown.
(F and G) The graphs show the quantification of the number of cells metastasized to the trunk region (at least n = 50 injections for each condition). Data are
presented as the average (±SEM) compared to the control condition from two independent experiments. For statistical analysis Kruskal-Wallis test was usedwith
Dunn’s post hoc test (***p < 0.001).
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RAPGEF2 Degradation Controls Cell MigrationFailure to degrade RAPGEF2 in response to HGF results in
sustained Rap1 and integrin activity and prevents the HGF-
induced stimulation of epithelial cell migration.
A number of studies have reported seemingly contradictory
results on the role of Rap1 in the regulation of cell migration.
Indeed, it has been shown that either increased or decreased
activity of Rap1 promotes cell motility (Ahmed et al., 2012;
Freeman et al., 2010; Kim et al., 2012; Lyle et al., 2008; McSherry
et al., 2011; Ohba et al., 2001; Yajnik et al., 2003; Zheng et al.,
2009). Moreover, in cancer cells, both overactivation and inacti-
vation of Rap1 have been associated with increased metastasis.
These conflicting findings can be explained at least in part by cell
type-specific and tumor type-specific effects of Rap1 on cell582 Developmental Cell 27, 574–585, December 9, 2013 ª2013 Elsevmigration and invasiveness. Indeed, it has been reported that
activated Rap1 promotes the metastatic invasion of prostate
and pancreatic carcinoma cells but inhibits invasion of osteosar-
coma and squamous cell carcinoma cells.
Interestingly, preventing Rap1 activation (by ectopic expres-
sion of Rap1GAP) or cycling (by expressing a constitutively
active Rap1 mutant) inhibits the ability of melanoma cells to
extravasate from the microvasculature and form metastatic
lesions in the lungs, indicating that dynamic regulation of Rap1
activity is required for metastatic dissemination of melanoma
cells (Freeman et al., 2010). It is also important to mention that
various means, e.g., overexpression/activation of different
Rap1 GEFs or GAPs, overexpression of constitutively active, orier Inc.
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RAPGEF2 Degradation Controls Cell Migrationinactive Rap1 mutants, have been employed to manipulate
the activity of Rap1. These different strategies can affect distinct
cellular pools of Rap1, which, via different Rap1 effectors,
can lead to different outcomes. Furthermore, it is well estab-
lished that Rap1 controls multiple steps in the metastatic
cascade, from the initial movement through the stroma and
the intravasation into the blood and lymphatic vessels, to the
extravasation and invasion of the stroma of a second tumor
site. As a result, whereas a specific step might require activation
of the Rap1-integrin signaling and increased cell adhesion to
the extracellular matrix, a different step might benefit from
decreased Rap1/integrin activity and decreased adhesion. In
this regard, during HGF-induced cell scattering, we observe
a biphasic regulation of Rap1 with an initial rapid increase
of Rap1 activity, followed by its decrease. It is likely that
RAPGEF2 accounts for the initial rise in Rap1 activity, although
the role of other GEFs, such as C3G, cannot be ruled out at
this stage. It has been shown that RAPGEF2 acts not only as
an upstream activator of Rap1, but is in turn activated by
Rap1-GTP, via direct association of its RA domain with Rap1-
GTP (Hisata et al., 2007; Liao et al., 1999, 2001). This ensures
that once activated, RAPGEF2 triggers a positive activation
loop leading to the amplification of Rap1-mediated signaling.
We propose that IKKb- and CK1a-mediated degradation of
RAPGEF2 represents a mechanism to stop the RAPGEF2-
Rap1-GTP auto-amplification loop and inactivate Rap1-medi-
ated signaling, enabling cell migration.
The direct involvement of IKKb in the degradation of RAPGEF2
is intriguing. Indeed, the IKK complex is the major signaling node
of the NF-kB pathway, which regulates immune and inflamma-
tory responses. It is well established that inflammatory cells,
and in particular, tumor-associated macrophages, are present
at the invasive front of carcinomas where they stimulate motility
of tumor cells. Tumor-associated macrophages secrete proin-
flammatory cytokines, such as TNFa, which activate the IKK
complex and the downstream NF-kB signaling. By inducing
RAPGEF2 degradation and consequent inhibition of Rap, a
potent and ubiquitous activator of integrins, IKK would directly
control integrin-mediated epithelial cell adhesion, migration,
and polarity.
Although a number of molecular mechanisms underlying the
prometastatic function of the NF-kB signaling pathway have
been proposed, these are all based on the ability of NF-kB tran-
scription factors to translocate into the nucleus and control the
expression of genes involved in EMT (Snail), invasion, (matrix
metalloproteinase-9), and survival (BCL-XL, XIAP). Our study
suggests that the IKK complex can mediate motility and inva-
siveness of cancer cells in both transcription-dependent (via
the activation of NF-kB transcription factors) and -independent
(via degradation of the Rap1 activator RAPGEF2) manners.
Of note, we observe proteasome-dependent degradation of
RAPGEF2 in response to phorbol esters or HGF, regarded as
weaker activators of IKK if compared with proinflammatory cyto-
kines such as TNFa (Fan et al., 2005, 2007, 2009; Hah and Lee,
2003; Huang et al., 2003; Mu¨ller et al., 2002). Interestingly, we
detect an accelerated degradation of RAPGEF2 when cells are
treated with both HGF and TNFa, suggesting a synergistic action
of these two growth factors on RAPGEF2 proteolysis
(Figure S4R).DevelopmIn conclusion, we have shown that HGF induces rapid protea-
somal degradation of the Rap activator RAPGEF2 and that
expression of a nondegradable mutant of RAPGEF2 inhibits
epithelial cell migration. Moreover, we have demonstrated that
inhibition of RAPGEF2 degradation dramatically suppresses
invasion and dissemination of breast cancer cells. A plethora
of genetic and biochemical data have demonstrated that HGF,
produced by stromal cells, and its tyrosine kinase receptor
MET, present in tumor cells, play a causal role in metastasis
formation during cancer progression. Notably, somatic and
germline mutations, as well as amplification of the MET locus,
are frequently found in human tumors. We suggest that, by inhib-
iting epithelial cell motility and invasion, degradation-resistant
forms of RAPGEF2 might provide beneficial effects against the
metastatic spread of cancer cells.
EXPERIMENTAL PROCEDURES
Gene Silencing by Small Interfering RNA
The sequence and validation of the oligonucleotides corresponding to bTrCP1
and bTrCP2 were previously published (Guardavaccaro et al., 2008). Cells
were transfected with the oligonucleotides twice (24 and 48 hr after plating)
using Oligofectamine (Invitrogen) according to manufacturer’s recommenda-
tions. Forty-eight hours after the last transfection, lysates were prepared and
analyzed by immunoblotting.
Zebrafish
All zebrafish strains were maintained at the Hubrecht Institute under standard
husbandry conditions. The transgenic line used was Tg(fli1a:egfp)y1 (Lawson
and Weinstein, 2002).
Invasion Assay in Zebrafish
Zebrafish were grown in 75 mM 1-phenyl 2-thiourea (PTU) (Sigma-Aldrich)
dissolved in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4). Cells for injections were labeled with the lipophilic tracer
DiI (Invitrogen) 12 hr before injection. Cells were trypsinized and dissolved in
PBS at the concentration of 400 cells/nl. Approximately 800 cells (2 nl) were
injected into the perivitelline space of 48 hpf zebrafish embryos. Neovascula-
rization and metastasis were monitored and quantified.
Imaging of Zebrafish Embryos
Embryos were mounted in 0.5%–1% low melting point agarose (Invitrogen)
dissolved in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mMMgSO4) on a culture dish with a glass coverslip replacing the bottom.
Imaging was performed with a Leica SP2 confocal microscope (Leica Micro-
systems) using a 103 or 203 objective with digital zoom.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2013.10.023.
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Figure S1 (continued). βTrCP targets RAPGEF2 for degradation in response to 
HGF, Related to Figure 1 
(A) Peptide coverage of RAPGEF2 in the mass spectrometry analysis of βTrCP2 
immunopurification.  
(B) Peptide coverage of βTrCP1/FBXW1, βTrCP2/FBXW11, Cul1, Skp1 and Rbx1 in the 
mass spectrometry analysis of RAPGEF2 immunopurification.  
(C) Peptide coverage of Rap1A, Rap1B, Rap2B and Rap2C in the mass spectrometry 
analysis of RAPGEF2 immunopurification.  
Amino acid sequences of detected unique peptides are highlighted in yellow.   
(D, E) MDCK cells were treated with EGF (D) or IGF (E), collected at the indicated times 
and lysed. Whole cell extracts were analyzed by immunoblotting. Cul1 is shown as a 
loading control. 
(F) HEK293 cells were treated with HGF in the presence or absence of the proteasome 
inhibitor MG132. Cells were collected at the indicated times and lysed. Whole cell 
extracts were subjected to immunoblotting. Actin is shown as a loading control. !!
 !!!!!!!!!!!!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. The RAPGEF2 degron is phosphorylated by CK1α ,  Related to Figure 2   
(A) Graphical summary of the RAPGEF2 conserved domains. Sequence and position of 
the βTrCP-binding domain are shown. 
(B) HEK293 cells expressing either HA-tagged wild type RAPGEF2 or HA-tagged 
RAPGEF2(S1244A/S1248A) were treated with HGF and MG132 for 4 hours before 
harvesting. Whole cell extracts were immunoprecipitated with anti-HA resin followed by 
immunoblotting with antibodies specific for the indicated proteins.  
(C) HEK293 cells expressing HA-tagged wild type RAPGEF2 were treated with HGF and 
MG132 for 4 hours before harvesting. Whole cell extracts were subjected to 
immunoprecipitation with anti-HA resin. When indicated, the immunocomplexes were 
incubated with lambda phosphatase for 30 minutes and then subjected to 
immunoblotting with antibodies specific for the indicated proteins.  
(D) Peptide coverage of CK1α in the mass spectrometry analysis of RAPGEF2 
immunopurification. Amino acid sequences of detected unique peptides are highlighted 
in yellow.  
(E) HEK293T cells were transfected with the indicated plasmids. After 48 hours, cells 
were treated with MG132 for 5 hours. Cells were lysed and whole cell extracts were 
subjected to immunoprecipitation using anti-HA resin before immunoblotting with 
antibodies for the indicated proteins. 
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Figure S3. Continued on the next page. 
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Figure S3 (continued). IKKβ-mediated phosphorylation of RAPGEF2, Related to 
Figure 3  
(A) Alignment of the amino acid regions corresponding to IKK target sites in RAPGEF2 
orthologs and previously reported IKK substrates (highlighted in grey). The upstream 
RAPGEF2 degron is highlighted in black. 
(B) Cells were treated as indicated, collected and lysed. Whole cell extracts were 
subjected to immunoblotting with antibodies specific for the indicated proteins. 
(C) Immunopurified wild type RAPGEF2 or RAPGEF2(S1244A/S1248A) were first 
dephosphorylated by treatment with lambda phosphatase and then incubated with the 
indicated purified kinases in the presence of ATP. Reactions were stopped by adding 
Laemmli buffer and analyzed by immunoblotting with antibodies for the indicated 
proteins. 
(D) Cells were transfected with the indicated siRNA oligonucleotides and treated with 
PMA. Cells were then collected at the indicated times and lysed. Whole cell extracts 
were analyzed by immunoblotting with antibodies specific for the indicated proteins. Cul1 
is shown as a loading control 
(E) HEK293T cells were transfected with the indicated cDNAs. After 48 hours, cells were 
treated with MG132 for 5 hours. Cells were lysed and whole cell extracts were subjected 
to immunoprecipitation using anti-HA resin before immunoblotting with antibodies for the 
indicated proteins. 
(F, G) RAPGEF2 was immunopurified and dephosphorylated with lambda phosphatase 
prior to an in vitro kinase assay in the presence of purified IKKβ, CK1α, CK2, or RSK1. A 
mock reaction (no kinase) was used as a negative control. Individual mixes were 
subsequently trypsinized and analyzed by mass spectrometry. The RAPGEF2 tryptic 
peptide GSWTSCSSGSHDNIQTIQHQR was not found to be phosphorylated in any mix 
(F) except when IKKβ was used in the in vitro kinase assay. In this sample, the same 
peptide was found to be phosphorylated on Ser1254 (G). As shown, both peptide 
sequences can be explained by their respective ETD MSMS spectrum (Mascot Score 48 
and 52), including the pS1254 site (PhosphoRS site probability = 94.4%). In this figure, 
[c] denotes carbaminomethylated cysteine; [pS] denotes phosphorylated serine; [z’] 
denotes z+1 ions and [z*] denotes z+2 ions.  
(H) MDCK cells, transduced with lentiviruses expressing HA-tagged wild type RAPGEF2 
or HA-tagged RAPGEF2(S1254A), were treated with HGF and the inhibitor of protein 
synthesis cycloheximide (CHX). Cells were then collected and analyzed by 
immunoblotting with antibodies for the indicated proteins. Cul1 is shown as a loading 
control. The graph illustrates the quantification of RAPGEF2 abundance relative to the 
amount at time 0. 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Continued on the next page. 
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Figure S4 (continued). RAPGEF2 degradation is required for induction of cell 
migration in response to HGF. Related to Figure 4 
(A) Cells were mock-transduced or transduced with lentiviruses expressing HA-tagged 
wild type RAPGEF2 or RAPGEF2(S1244A/S1248A). Cells were collected and lysed. 
Whole cell extracts were analyzed by immunoblotting. A and B indicate cells from 
independent lentiviral transductions. 
(B) HEK293 cells transduced with lentiviruses expressing HA-tagged wild type 
RAPGEF2 or RAPGEF2(S1244A/S1248A) were treated with PMA. Cells were collected 
and analyzed by immunoblotting. Cul1 is shown as a loading control.  
(C) HEK293 cells, transduced as in (B), were treated with PMA and the inhibitor of 
protein synthesis cycloheximide (CHX). Cells were then collected and analyzed by 
immunoblotting. Actin is shown as a loading control.  
(D, E) MDCK cells, transduced as in (A), were treated with EGF (D) or PDGF (E). Cells 
were then collected and analyzed by immunoblotting. Cul1 is shown as a loading control. 
(F) MDCK cells, transduced as in (A), were treated with HGF for 4 hours. Cells were 
analyzed by indirect immunofluorescence. Scale bars, 50 µm.  
(G) An automated cell tracking software was employed to measure the average 
migration velocity of MDCK cells expressing wild type RAPGEF2 or 
RAPGEF2(S1244A/S1248A) in response to HGF. Only non-contacted cells (not starting 
from cell islands) were tracked. For each cell line/condition, 3 independent time-lapse 
image series (at least 300 individual cells) were analyzed.  
(H) Representative individual migratory tracks of non-contacted MDCK cells expressing 
wild type RAPGEF2 or RAPGEF2(S1244A/S1248A) in response to HGF. 
(I) Track distance of individual cells shown in (H). P < 0.001 (Student’s t-test).  
(J) MDCK cells transduced with lentiviruses expressing wild type RAPGEF2 or 
RAPGEF2(S1244A/S1248A) were cultured in low calcium (20 µM Ca2+). Cells were 
treated with HGF and imaged by time-lapse phase-contrast microscopy. Representative 
phase-contrast images from the time-lapse series are shown. Scale bars, 100 µm.  
(K) An automated cell tracking software was employed to measure the average 
migration velocity of MDCK cells expressing wild type RAPGEF2 or 
RAPGEF2(S1244A/S1248A) cultured in 20 µM Ca2+ in the presence of HGF. For each 
cell line/condition, 3 independent time-lapse image series were analyzed.  
(L) Representative individual migratory tracks of MDCK cells expressing wild type 
RAPGEF2 or RAPGEF2(S1244A/S1248A) cultured in 20 µM Ca2+ with HGF.  
(M) Track distance of individual cells shown in (L). Horizontal lines represent the mean. 
P = 0.00134 (Student’s t-test).  
(N) MDCK cells were transfected with either YFP or YFP-tagged Rap1V12 (a 
constitutively active Rap1 mutant). Cells were then treated with HGF and imaged by 
time-lapse microscopy for 12 hours. Representative individual migratory tracks of non-
contacted cells are shown.  
(O) Track distance of individual cells shown in (N). P < 0.001 (Student’s t-test). 
(P) MDCK cells transduced with lentiviruses expressing HA-tagged wild type RAPGEF2 
or RAPGEF2(S1244A/S1248A) were treated with HGF for 4 hours or left untreated. Cells 
were analyzed by indirect immunofluorescence. Scale bars, 20 µm.  
(Q) Quantification of immunofluorescence shown in (P). Cells were scored for bright 
edges (n = 3, ± SD). P < 0.001. 
(R) MDCK cells were treated with the indicated growth factors. Whole cell extracts were 
subjected to immunoblotting. Cul1 is shown as a loading control. To facilitate 
comparison, dotted lines separate samples from cells treated with different growth 
factors. 
EXTENDED EXPERIMENTAL PROCEDURES 
Cell culture and drug treatment   
HEK293T, HEK293, and MDCK cells were maintained in Dulbecco’s modified Eagle’s 
medium (Invitrogen) containing 10% fetal calf serum. To induce scattering, cells were 
serum starved for 16 hours and then treated with 10 ng/ml hepatocyte growth 
factor/scatter factor (HGF/SF, Sigma-Aldrich), or 10 ng/ml phorbol-12-myristate-13-
acetate (PMA, Sigma-Aldrich). EGF, IGF and PDGF were used at 10 ng/ml. The 
following drugs were used: MG132 (Peptide Institute; 10 µM), TBB (Merck Millipore, 75 
µM), D4476 (Sigma-Aldrich, 50 µM), IC261 (Sigma-Aldrich, 100 µM), SC-514 (Sigma-
Aldrich, 20 µM), cycloheximide (Sigma-Aldrich, 100 µM). 
 
Plasmids and small hairpin RNAs 
The mammalian expression plasmid for CK1α was provided by H. Clevers. For lentivirus 
production, wild type RAPGEF2 and RAPGEF2(S1244A/S1248A) were subcloned into 
the lentiviral vector pHAGE2-EF1α. The RAPGEF2 mutant was generated using the 
QuickChange Site-directed Mutagenesis kit (Stratagene). shRNAs targeting human 
CK1α were provided by W. Wei. All cDNAs were sequenced.   
 
Transient transfections and lentivirus-mediated gene transfer 
HEK293 and HEK293T cells were transfected using the polyethylenimine (PEI) method. 
For lentivirus production, HEK293T cells were co-transfected with pHAGE2-EF1a and 
packaging vectors. Virus-containing medium was collected 48-72 hours after transfection 
and supplemented with 8 µg/ml polybrene. Cells were incubated with virus-containing 
medium for 6 hours for 2 consecutive days. 
 
Purification of βTrCP2 interactors 
HEK293T cells were transfected with pcDNA3-FLAG-HA-βTrCP2 and treated with 10 µM 
MG132 for 5 hours. Cells were harvested and subsequently lysed in lysis buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP40, plus protease and 
phosphatase inhibitors). βTrCP2 was immunopurified with anti-FLAG agarose resin 
(Sigma-Aldrich). After washing, proteins were eluted by competition with FLAG peptide 
(Sigma-Aldrich). The eluate was then subjectHG to a second immunopurification with anti-
HA resin (12CA5 monoclonal antibody crosslinked to protein G Sepharose; Invitrogen) 
prior to elution in Laemmli sample buffer. The final eluate was separated by SDS-PAGE, 
and proteins were visualized by Coomassie colloidal blue. Bands were sliced out from 
the gels and subjected to in-gel digestion. Gel pieces were then reduced, alkylated and 
digested according to a published protocol (Shevchenko et al., 1996). For mass 
spectrometric analysis, peptides recovered from in-gel digestion were separated with a 
C18 column and introduced by nano-electrospray into the LTQ Orbitrap XL (Thermo 
Fisher) with a configuration as described (Raijmakers et al., 2008). Peak lists were 
generated from the MS/MS spectra using MaxQuant build 1.0.13.13 (Cox and Mann, 
2008), and then searched against the IPI Human database (version 3.37, 69164 entries) 
using Mascot search engine (Matrix Science). Carbaminomethylation (+57 Da) was set 
as fixed modification and protein N-terminal acetylation and methionine oxidation as 
variable modifications.  Peptide tolerance was set to 7 ppm and fragment ion tolerance 
was set to 0.5 Da, allowing 2 missed cleavages with trypsin enzyme. Finally, Scaffold 
3.6.1 (Proteome Software Inc.) was used to validate MS/MS based peptide and protein 
identifications. Peptide identifications were accepted if their Mascot scores exceeded 20. 
 
Phosphorylation analysis by mass spectrometry 
Samples were reduced with 10 mM DTT for 30 minutes at 60˚C, followed by addition of 
iodoacetamide to 20 mM followed by 30-minute incubation in the dark at room 
temperature. The first digestion was performed using Lys-C for 4 hours at 37˚C.  
Subsequently, the digest was diluted 5-fold using 50 mM ammonium bicarbonate to a 
final urea concentration of less than 2 M, and a second digestion with trypsin was 
performed overnight at 37˚C. Finally, the digestion was quenched by addition of formic 
acid to a final concentration of 0.1% (vol/vol). The resulting solution was desalted using 
200 mg Sep-Pak C18 cartridges (Waters Corporation), lyophilized and reconstituted in 
10% formic acid. LC-MS/MS was performed with both collision-induced dissociation and 
electron transfer dissociation in the form of data-dependent decision tree!(Frese et al., 
2011; Swaney et al., 2008). MS spectra to peptide sequence assignment is performed 
with Proteome Discoverer Version 1.3, with MASCOT version 2.3 as search engine and 
the localization of phosphorylated sites was evaluated with PhosphoRS version 2!(Taus 
et al., 2011). 
 
Biochemical methods 
Extract preparation, immunoprecipitation, and immunoblotting were previously described 
(Kruiswijk et al., 2012). Monoclonal antibodies were from Invitrogen (Cul1), Sigma-
Aldrich (FLAG), Santa Cruz Biotechnology (Actin), BD Biosciences (β-catenin, Rap2, 
active β1-integrin), Cell Signaling [IκBα, phospho-IκBα(Ser32/Ser36)] and Covance 
(HA). Rabbit polyclonal antibodies were from Cell Signaling [(βTrCP1, 
CK1α, IKKβ, phospho-IKKβ(Ser177)], Sigma-Aldrich (FLAG), Novus Biologicals 
(RAPGEF2) and Santa Cruz (Rap1).  
 
In vitro kinase assay 
Immunopurified RAPGEF2 was first dephosphorylated by treatment with lambda 
phosphatase and then incubated at 30°C for 30 minutes with 0.2 mM ATP and the 
indicated kinases in a 20 µl of kinase buffer (25 mM Tris pH 7.5, 10 mM MgCl2, 2 mM 
DTT, 5 mM β-glycerophosphate, 0.1 mM sodium orthovanadate). Reaction products 
were subjected to immunoblotting. Autoradiography was performed when γ32P ATP was 
used. For sequential in vitro kinase assay (Figure 3B), immunopurified RAPGEF2 was 
subjected to a first phosphorylation reaction (30 minutes) with the indicated purified 
kinases. Samples were then washed three times in lysis buffer (50 mM Tris-HCl pH 7.5, 
250 mM NaCl, 0.1% Triton X-100, 1 mM EGTA) to remove the first kinase and twice in 
kinase buffer. Samples were then subjected to a second phosphorylation reaction with 
CK1α as described above. 
 
In vitro ubiquitylation assay   
RAPGEF2 ubiquitylation was performed in a volume of 10 µl containing SCFβTrCP- 
RAPGEF2 immunocomplexes, 50 mM Tris pH 7.6, 5 mM MgCl2, 0.6 mM DTT, 2 mM 
ATP, 1.5 ng/µl E1 (Boston Biochem), 10 ng/µl Ubc3, 2.5 µg/µl ubiquitin (Sigma-Aldrich), 
1 µM ubiquitin aldehyde. The reactions were incubated at 30°C for 60 minutes and 
analyzed by immunoblotting.  
 
Live cell microscopy 
Cell scattering in MDCK cells was analyzed as previously described (Lyle et al., 2008). 
MDCK cells were seeded at low density in 48-well plates coated with 10 µg/ml collagen 
and allowed to grow in small colonies. The following day, cells were rinsed and 
incubated in Dulbecco’s modified Eagle’s medium containing 0.5 % FBS and 20 mM 
Hepes, pH 7.4. All wells were completely filled with medium and the plate was sealed 
using silicon grease and a glass plate. Images were acquired every 10 minutes using a 
10X objective lens in a climate-controlled incubator. A robotic stage was used to 
simultaneously collect images at different positions. Cells were imaged in absence of 
HGF for the first 2 hours, after which, 10 ng/ml HGF was added. Cells were then filmed 
for additional 12-16 hours. At least three time-lapse series were acquired for each 
condition in each experiment. 
 
Analysis of cell scattering in time-lapse movies 
The software employed to automatically track cell scattering has been previously 
described (Lyle et al., 2008). Briefly, this software detects and tracks single cells in the 
time-lapse images of scattering cells and determines their velocity throughout the 
process of scattering. Only cells that were faithfully tracked for at least 6 consecutive 
frames and stayed “single” during that period of time were considered. The velocity was 
calculated as the displacement (µm) over three consecutive frames, divided by the 
elapsed time (10 minutes). 
 
Rap activation assay 
Rap1 and Rap2 activity was analyzed as described (Franke et al., 1997).   
 
Wound healing assay  
Wound healing assay was performed as described (Buus et al., 2009). MDCK cells were 
seeded in a 6-well plate at 1 x 106 cells per well and starved overnight in 0.5% FBS 
containing medium. The following day, a linear scratch in the confluent cell monolayer 
was made with a sterile pipette tip. Cells were rinsed and supplemented with 10 ng/ml 
HGF for 8 hours. For each well 3 pictures were taken at 4X magnification along the 
scratch area.  
 
Invasion assay in vitro 
In vitro invasion assays were performed in 24-well ThinCert cell culture inserts 
(Greinerbioone, 8.0-µm pore size). MDA-MB-231 cells were serum starved overnight. 
The following day, 50x103 or 10x104 cells were plated in pre-coated transwell inserts (at 
least three replicas for each sample). HGF (10 ng/ml) was added to the lower 
compartment. After 8 hours, cells were fixed in 4% paraformaldehyde and stained with 
0.5% crystal violet. Filters were photographed in 4 random fields and the number of cells 
counted. Every experiment was repeated independently at least three times. 
 
Statistical analysis 
Statistical analysis was performed using Pearson’s Chi-Square or Student’s t-test. 
Results with P < 0.05 were considered statistically significant. 
Kruskal-Wallis and Dunn’s post-hoc tests were used for the statistical analysis of the 
zebrafish xenograft experiments. 
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